Zentalis Pharmaceuticals Inc Ordinary Shares ZNTL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ZNTL is a good fit for your portfolio.
News
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
-
Zentalis Pharmaceuticals Shares Slide on Partial Clinical Holds on Cancer Drug Studies
-
Zentalis Pharmaceutical Studies on Partial Clinical Hold Following Deaths
Trading Information
- Previous Close Price
- $3.48
- Day Range
- $3.27–3.66
- 52-Week Range
- $3.27–29.03
- Bid/Ask
- $3.37 / $3.90
- Market Cap
- $257.07 Mil
- Volume/Avg
- 1.3 Mil / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.10
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 168
- Website
- https://www.zentalis.com
Comparables
Valuation
Metric
|
ZNTL
|
MRSN
|
KURA
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.56 | 8.00 | 3.02 |
Price/Sales | 6.10 | 5.71 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
ZNTL
|
MRSN
|
KURA
|
---|---|---|---|
Quick Ratio | 8.92 | 3.43 | 16.34 |
Current Ratio | 9.19 | 3.51 | 16.67 |
Interest Coverage | — | −34.91 | −116.04 |
Quick Ratio
ZNTL
MRSN
KURA
Profitability
Metric
|
ZNTL
|
MRSN
|
KURA
|
---|---|---|---|
Return on Assets (Normalized) | −21.15% | −41.22% | −28.85% |
Return on Equity (Normalized) | −25.95% | −196.75% | −31.62% |
Return on Invested Capital (Normalized) | −23.67% | −129.55% | −33.98% |
Return on Assets
ZNTL
MRSN
KURA
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Bnttcttvx | Bdkcc | $628.7 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Nkbyffndk | Xwdpfv | $122.5 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Ppsmbzw | Ywfmrv | $114.0 Bil | |||
Moderna Inc
MRNA
| Gwrhywb | Zgd | $45.3 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Dybrvzz | Yjmzvrj | $31.8 Bil | |||
argenx SE ADR
ARGX
| Gprtfkrs | Pgvyx | $25.9 Bil | |||
BioNTech SE ADR
BNTX
| Gypyqvfnn | Xfzw | $19.3 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Bsxtzhhw | Xcccphf | $15.5 Bil | |||
United Therapeutics Corp
UTHR
| Xnnmfwr | Fvm | $14.0 Bil | |||
Royalty Pharma PLC Class A
RPRX
| Jlxngvrhk | Wtrwdyt | $11.6 Bil |